13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02104661
(ClinicalTrials.gov)
October 20141/4/2014Protective Role of Oxcarbazepine in Multiple SclerosisOxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a TrialMultiple SclerosisDrug: Oxcarbazepine;Drug: PlaceboQueen Mary University of LondonNational Multiple Sclerosis Society;Novartis Pharmaceuticals;Barts & The London NHS Trust;University College, London;Royal Free Hospital NHS Foundation Trust;Southend University Hospital;Basildon and Thurrock University Hospitals NHS Foundation Trust;St George's Healthcare NHS Trust;Barnet and Chase Farm Hospitals NHS TrustCompleted18 Years60 YearsAll30Phase 2United Kingdom
2EUCTR2013-002419-87-GB
(EUCTR)
18/03/201407/02/2014 PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis) Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial - PROXIMUS - PRotective role of OXcabazepine In MUltiple Sclerosis Multiple sclerosis
MedDRA version: 19.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Trileptal
Product Name: Oxcarbazepine
INN or Proposed INN: oxcarbazepine
Other descriptive name: Trileptal
Queen Mary University LondonNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom